Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Massachusetts
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Massachusetts keessatti
Qorannoo 45 Leukemia Myeloidii Hamaa f Massachusetts keessatti hirmaatuu jiru.
Magaalota Massachusetts keessatti
Takkalaa qorannoo (Ingiliffa)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564390Ivosidenib as Post-HSCT Maintenance for AML
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06707493Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Lahey Clinic, Burlington
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06852222Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- fi 2 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT05554406Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- fi 2 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06317649A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Dana-Farber Cancer Center, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
Namoota walitti qabaa jiraSadarkaa 3
6 Months – 21 Years · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04293562(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT03471260Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT04588922CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 90 · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT07439211Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT06533761The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Hanga umuriin 22 · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04726241A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT05886049Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 3
29 Days – 21 Years · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT06001788A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 28-Ado-2026 · NCT07020533A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT01351545A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 17-Wax-2026 · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Wax-2026 · NCT06138587SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Wax-2026 · NCT03113643Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- fi 2 dabalataa
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Cam-2026 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 13 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT04771572Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin hundi · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT07374029A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Elb-2026 · NCT04256317BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 01-Elb-2026 · NCT06660368Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 25-Bit-2026 · NCT06313437A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 24-Bit-2026 · NCT04988555Ziftomenib Maintenance Post Allo-HCT
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Bit-2026 · NCT06440135A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 66 · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 16-Bit-2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT05735184CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 10-Bit-2026 · NCT06059391A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- DFCI, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Gur-2026 · NCT06950034A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Gur-2026 · NCT07148180Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.